Related Experiment Video
Updated: Nov 11, 2025
07:36
Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
Published on: May 16, 2020
5.6K
Targeted Therapies for Follicular Lymphoma
Jennifer Girard1, Yasmin Karimi1, Shannon Carty1
1Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48130, USA.
Current Hematologic Malignancy Reports
|March 23, 2021
Summary
Follicular lymphoma (FL) is an incurable cancer. Newer targeted therapies and immunotherapies show promise for patients with relapsed or refractory disease, improving outcomes compared to traditional chemotherapy.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Follicular lymphoma (FL) is the second most common lymphoma in Western countries.
- While often incurable, many patients survive over a decade, but some experience early relapse (POD24) with poorer prognoses.
- Treatment has evolved from observation and radiation to systemic therapies, including rituximab and targeted agents.
Purpose of the Study:
- To review the evolving treatment landscape for follicular lymphoma.
- To highlight recent advancements in systemic therapies, particularly for relapsed/refractory disease.
- To discuss the impact of novel agents targeting specific mutations and the immune system.
Main Methods:
- Review of current literature and clinical trial data on follicular lymphoma treatments.
- Analysis of treatment outcomes with traditional and novel therapeutic agents.
- Focus on advancements in relapsed/refractory and POD24 settings.
Main Results:
- Newer agents, including lenalidomide and tazemetostat, demonstrate encouraging outcomes in relapsed/refractory FL.
- Targeted therapies and immunotherapies offer alternatives to cytotoxic chemotherapy, especially for difficult-to-treat subtypes.
- Early data on immune-system-harnessing agents are promising.
Conclusions:
- Follicular lymphoma treatment has significantly improved with novel agents.
- Targeted therapies and immunotherapies represent a paradigm shift, offering new hope for patients.
- Continued research into biological drivers and immune-based strategies may lead to a cure.
Keywords:
.
Related Concept Videos
02:57Targeted Cancer Therapies
8.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.1K
01:27Tumor Immunotherapy
820
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
820
02:50Combination Therapies and Personalized Medicine
5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
02:49Cancer Therapies
8.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.9K
01:26Targets for Drug Action: Overview
8.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.9K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
285
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
285